Article
Cardiac & Cardiovascular Systems
M. V. Basalay, James M. Downey, S. M. Davidson, D. M. Yellon
Summary: This study aimed to investigate the impact of aspirin on remote ischemic conditioning (RIC) in the treatment of myocardial infarction. The results showed that aspirin did not affect the infarct-limiting effect of RIC.
CARDIOVASCULAR DRUGS AND THERAPY
(2023)
Article
Hematology
Karsten Schroer, Freek W. A. Verheugt, Dietmar Trenk
Summary: Lipid-lowering agents and antiplatelet drugs are standard treatments for secondary prevention of acute thrombotic events. Aspirin inhibits platelet-dependent thromboxane formation and improves endothelial oxygen defense, while statins reduce LDL-C levels and inhibit platelet function. PCSK9 antibodies target PCSK9, which impacts LDL-C plasma levels and platelet signaling. These drugs have synergistic effects and can reduce the incidence of atherothrombotic vascular events.
THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Multidisciplinary Sciences
Cajetan Immanuel Lang, Praveen Vasudevan, Piet Doering, Ralf Gaebel, Heiko Lemcke, Tobias Lindner, Gustav Steinhoff, Bernd Joachim Krause, Brigitte Vollmar, Felix G. Meinel, Seyrani Yuecel, Alper Oener, Hueseyin Ince, Robert David
Summary: This study investigated post-infarct remodeling after acute myocardial infarction using mouse models and magnetic resonance imaging. The results showed differences in cardiac remodeling between the permanent ligation (PL) and ischemia reperfusion (I/R) models. Different methods of analysis revealed that PL resulted in significant left ventricle dilation and decreased contractile function, while the effects were less pronounced in the I/R model.
SCIENTIFIC REPORTS
(2021)
Article
Cardiac & Cardiovascular Systems
Yochai Birnbaum, Regina Ye, Yumei Ye
Summary: Aspirin loading may explain the lack of success of ischemic postconditioning in clinical practice.
CARDIOVASCULAR DRUGS AND THERAPY
(2023)
Review
Clinical Neurology
Adam de Havenon, Kevin N. Sheth, Tracy E. Madsen, Karen C. Johnston, Tanya N. Turan, Kazunori Toyoda, Jordan J. Elm, Joanna M. Wardlaw, S. Claiborne Johnston, Olajide A. Williams, Ashkan Shoamanesh, Maarten G. Lansberg
Summary: Cilostazol is a safe drug approved for the treatment of claudication in peripheral arterial disease patients and secondary stroke prevention in Asian countries. While it reduces the risk of stroke recurrence in noncardioembolic stroke patients, it may cause adverse effects such as headache, gastrointestinal symptoms, and palpitations.
Article
Biochemistry & Molecular Biology
Rolf Schreckenberg, Annemarie Wolf, Tamara Szabados, Kamilla Gomori, Istvan Adorjan Szabo, Gergely Agoston, Gabor Brenner, Peter Bencsik, Peter Ferdinandy, Rainer Schulz, Klaus-Dieter Schlueter
Summary: Hypoxia upregulates PCSK9 in the heart, which affects myocyte function. Genetic deletion of PCSK9 or antagonism of circulating PCSK9 reduces reperfusion injury. A high-fat diet decreases survival rate during reperfusion, likely due to increased MMP9 activity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cardiac & Cardiovascular Systems
Satoshi Miyashita, Taro Kariya, Kelly P. Yamada, Olympia Bikou, Serena Tharakan, Navin K. Kapur, Kiyotake Ishikawa
Summary: LVAD therapy significantly reduces infarct size in experimental acute myocardial infarction, with early initiation and effective left ventricle venting being important factors.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
David Schumacher, Elisa A. Liehn, Anjana Singh, Adelina Curaj, Erwin Wijnands, Sergio A. Lira, Frank Tacke, Joachim Jankowski, Erik A. L. Biessen, Emiel P. C. van der Vorst
Summary: The study found that CCR6 plays an important role in ischemia-reperfusion injury after acute myocardial infarction, exerting protective effects on the heart through bone marrow cells. Increasing CCR6-dependent immune mechanisms may represent an interesting therapeutic target for cardiac damage and inflammation.
Review
Cardiac & Cardiovascular Systems
Regina Ye, Hani Jneid, Mahboob Alam, Barry F. Uretsky, Dan Atar, Masafumi Kitakaze, Sean M. Davidson, Derek M. Yellon, Yochai Birnbaum
Summary: Aspirin loading is recommended for patients with ST elevation myocardial infarction (STEMI) as soon as possible after presentation, but its effects on the therapeutic effects of other medications have not been studied. This review suggests that aspirin loading may attenuate the protective effects of statins, ticagrelor, morphine, and postconditioning in reducing myocardial infarct size. Further research is needed to investigate the effects of aspirin loading on these medications and to compare aspirin loading with alternative antiplatelet regimens in STEMI patients.
CARDIOVASCULAR DRUGS AND THERAPY
(2022)
Article
Hematology
Jonathan H. Chow, Ying Yin, David P. Yamane, Danielle Davison, Ryan J. Keneally, Katrina Hawkins, K. Gage Parr, Mustafa Al-Mashat, Jeffery S. Berger, Reamer L. Bushardt, Michael A. Mazzeffi, Stuart J. Nelson
Summary: A large observational study of COVID-19 patients found that prehospital antiplatelet therapy was associated with significantly lower in-hospital mortality. The study suggests that further randomized controlled trials are needed to determine the ultimate utility of antiplatelet therapy in COVID-19 patients with high rates of comorbidities.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Review
Clinical Neurology
Martin Valis, Blanka Klimova, Michal Novotny, Roman Herzig
Summary: This mini-review discusses the main antiplatelet agents used in the secondary prevention of non-cardioembolic ischemic stroke and TIA, with a focus on aspirin. The findings suggest that early antiplatelet therapy can improve neurological outcomes and reduce the chance of early subsequent stroke.
FRONTIERS IN NEUROLOGY
(2021)
Article
Pharmacology & Pharmacy
Zuzana Huskova, Sona Kikerlova, Janusz Sadowski, Petra Alanova, Lenka Sedlakova, Frantisek Papousek, Jan Neckar
Summary: The study confirmed improved cardiac tolerance to ischemia/reperfusion injury in hypertensive cardiohypertrophied rats and found that locally produced ANG II in the heart, through activation of AT1 receptors, was not the mechanism underlying infarct size reduction.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Alan Zakko, Liam Zakko, Alyssa A. Grimshaw, Loren Laine
Summary: The use of antiplatelet monotherapy in patients undergoing sphincterotomy during ERCP is associated with an increased risk of post-procedure bleeding based on systematic review and meta-analysis. However, the quality of existing studies is limited and further high-quality research is required to confirm these findings.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Medicine, Research & Experimental
Abdallah M. Gendy, Mohamed M. Amin, Asmaa K. Al-Mokaddem, Mohamed F. Abd Ellah
Summary: Cilostazol, a phosphodiesterase-III inhibitor, has been shown to have protective effects against intestinal ischemia/reperfusion-induced lung injury, partly by modulating oxidative stress, inflammation, and apoptosis mechanisms.
Article
Pharmacology & Pharmacy
Abigail R. Bland, Fergus M. Payne, John C. Ashton, Tannaz Jamialahmadi, Amirhossein Sahebkar
Summary: During cardiac reperfusion after myocardial infarction, the heart faces ischaemia reperfusion injury (IRI) which leads to myocardial dysfunction and cell death. Research has identified potential targeted therapies focusing on mitochondria, such as opening of the mitochondrial permeability transition pore, activation of mitoK(ATP) channels, and inhibition of GSK3 beta phosphorylation, to reduce the severity of myocardial IRI. Additionally, statins have shown direct cardioprotective effects on specific mitochondrial components, indicating their potential as a preconditioning agent.
PHARMACOLOGICAL RESEARCH
(2022)
